Outcomes with conventional allogeneic hematopoietic cell transplantation (HCT) after failed HCT are typically poor. To reduce transplantation-related mortality (TRM), 55 patients (median age, 43 years; range, 18-69 years) who had failed conventional autologous (n ‫؍‬ 49), allogeneic (n ‫؍‬ 4), or syngeneic (n ‫؍‬ 2) HCT received human leukocyte antigen-matched related (n ‫؍‬ 31) or unrelated (n ‫؍‬ 24) donor allografts after nonmyeloablative conditioning with 2 Gy of total body irradiation or 2 Gy of total body irradiation and 90 mg/m 2 of fludarabine. Postgrafting immunosuppression consisted of cyclosporine and mycophenolate mofetil. One rejection occurred. Thirty-three patients died a median of 127 days (range, 7-834 days) after HCT: 21 of relapse, 11 of TRM, and 1 of suicide. The TRM rate on day 100 was 11% with an estimated 1-year TRM rate of 20% (95% confidence interval [CI], 9% to 31%). The median follow-up among the 22 survivors is 368 days (range, 173-796 days). Seventeen of 22 survivors are progression-free. One-year estimates of overall and progression-free survival rates are 49% (95% CI, 35% to 62%) and 28% (95% CI, 16% to 41%), respectively. Untreated disease at the time of allografting after nonmyeloablative conditioning increased the risk of death (hazard ratio ‫؍‬ 2.4; P ‫؍‬ .04). Although the length of follow-up is still short, it appears that encouraging outcomes can be achieved with nonmyeloablative conditioning in patients expected to have poor outcomes with conventional allografting.
INTRODUCTION
For patients with hematologic malignancies who fail conventional allogeneic or autologous hematopoietic cell transplantations (HCT) because of relapse, rejection, or development of new secondary malignancies, options are limited. Patients with previous allografts may receive donor lymphocyte infusions (DLI) or second allogeneic HCT. Patients with previous autografts are often considered for salvage allogeneic HCT. Whereas DLI can induce durable remissions in patients with relapsed chronic myelogenous leukemia, its efficacy in treating other hematologic malignancies in relapse after transplantation is less impressive [1, 2] . Hence, salvage allografting is the only option with curative intent for many patients. Unfortunately, outcomes with conventional allografting after failed autologous or allogeneic HCT are typically poor owing to high transplantation-related mortality (TRM) [3] [4] [5] [6] [7] [8] [9] .
Recently, efforts have been made to decrease TRM with reduced-intensity conditioning regimens that rely specifically on graft-versus-tumor effects to eradicate malignancy [10] [11] [12] [13] [14] [15] [16] [17] [18] . A nonmyeloablative regimen using low-dose total body irradiation (TBI) with or without fludarabine and postgrafting immunosuppression with cyclosporine (CSP) and mycophenolate mofetil (MMF) has shown feasibility and efficacy for patients with human leukocyte antigen (HLA)-matched related and unrelated donors who were considered ineligible for high-dose HCT based on age or medical infirmity [19] [20] [21] [22] . This report describes outcomes for 55 patients with hematologic malignancies who received allografts after nonmyeloablative conditioning after having failed treatment with conventional HCT, mostly autologous.
MATERIALS AND METHODS

Patient Characteristics and Eligibility
Between January 1999 and July 2001, 55 patients (median age, 43 years; range, 18-69 years) underwent allografting after nonmyeloablative conditioning after failing conventional HCT. Patient diagnoses and histories of previous HCTs are listed in Table 1 . Patients with non-Hodgkin's lymphoma (NHL) were categorized as having aggressive disease, based on intermediate-or high-grade histology, or indolent disease, based on low-grade histology. Treatment centers included the Fred Hutchinson Cancer Research Center, University of Washington Medical Center, VA Puget Sound Health Care System, University of Leipzig (Germany), University of Colorado, Stanford University, City of Hope National Medical Center, Baylor University, and University of Utah. HLA matching included serological analysis for HLA-A, -B, and -C and allele level typing for HLA-DRB1 and DQB1. Eligibility requirements included the following: (1) creatinine clearance level Ͼ50 mL/min, (2) total bilirubin level Ͻ2 times normal, and (3) Karnofsky performance score Ͼ50. All patients were considered ineligible for conventional allografts because of age (older than 30 years), medical infirmity, or high risk of transplantation-related death. High risk was assumed to be present in those patients whose previous conditioning regimens had included high doses of TBI or who had otherwise dose-limiting local irradiation, eg, patients with NHL or Hodgkin's disease (HD).
Patients had either previous autologous (n ϭ 49), allogeneic (n ϭ 4), or syngeneic (n ϭ 2) HCT (Table  1) . Five patients had more than 1 previous HCT. Forty-six patients underwent allografting after nonmyeloablative conditioning for relapsed disease, 6 for new secondary malignancies, 2 for both relapse and new secondary malignancies, and 1 for autologous graft failure. Twelve patients had disease that had remained untreated after having failed conventional HCT. Thirty patients had treatment-responsive disease and 13 had treatment-refractory disease at the time of nonmyeloablative conditioning. All 9 patients with myelodysplastic syndrome (MDS) (refractory anemia ϭ 3, refractory anemia with excess blasts in transformation ϭ 3, acute myeloid leukemia inductin failure ϭ 1, agnogenic myeloid metaplasia ϭ 1, and acute myelogenous leukemia (AML) ϭ 1) had evidence of disease at HCT. Seven of the 9 patients with MDS had secondary MDS that had developed after high-dose autologous HCT for NHL (n ϭ 3), fallopian tube carcinoma (n ϭ 1), AML (n ϭ 1), breast cancer (n ϭ 1), or multiple myeloma (MM) (n ϭ 1). The 8 patients with MM had either partial remissions (PRs) (n ϭ 6) or were in relapse (n ϭ 2). The 15 patients with HD had either refractory disease (n ϭ 2), were in relapse (n ϭ 4), had PR (n ϭ 7), or were in complete remission (CR) (n ϭ 2). The 17 patients with NHL had either refractory disease (n ϭ 3), were in relapse (n ϭ 9), had PR (n ϭ 1), or were in CR (n ϭ 4). The 3 patients with chronic myeloid leukemia had evidence of disease at transplantation; 1 patient was in chronic phase, 1 in accelerated phase, and 1 in blast crisis. One patient with acute lymphocytic leukemia was in second CR and 1 was in fourth CR. The patient with AML was in fourth CR. The 3 patients with chronic myeloid leukemia were originally Philadelphia chromosome-positive. Additional cytogenetic studies were available at the time of HCT in 24 of the remaining 52 patients. Seven of the 24 (MDS ϭ 5, MM ϭ 2) had complex chromosomal abnormalities. The median duration from the time of conventional HCT to nonmyeloablative conditioning was 22 months (range, 2-128 months).
Treatment and Evaluation
The first 7 patients with HLA-matched related donors were conditioned with 2 Gy of TBI given at 7 cGy/min from dual cobalt-60 sources or linear accelerators on day 0. To reduce the risk of rejection, fludarabine, 30 mg/m 2 per day on days Ϫ4 to Ϫ2, was ---NHL-I  3  3  ----HD  15  14  ----1  MM  8  5  2  1  ---MDS  7  7  -----CML  3  ---2  1  -AL  3  1  --1  -1 AL indicates acute leukemia; Allo, allogeneic transplantation; Auto, autologous transplantation; NHL, A-Non Hodgkin's lymphoma-Aggressive; NHL-I, non-Hodgkin's lymphoma-Indolent; Syn, Syngeneic transplant.
*Two patients with relapsed NHL also had secondary MDS.
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added to the preparative regimen for the subsequent 24 patients [20] . Granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells (G-PBMC) were infused on day 0. The median CD34 cells/kg, respectively. As a means of dealing with the theoretical increased incidence of graft-versus-host disease (GVHD) compared with the HLA-matched related recipients, postgrafting immunosuppression was extended, and patients with unrelated donors received CSP, 6.25 mg/kg orally twice daily on days Ϫ3 to ϩ100, then tapered off by day ϩ180, and MMF, 15 mg/kg twice daily on days 0 to ϩ40, then tapered off by day ϩ96. CSP levels were targeted to the upper therapeutic range (approximately 500 ng/mL; Abbott TDX, Abbott Park, IL) until day ϩ28. The degrees of donor chimerism among peripheral blood T cells, granulocytes, and unfractionated marrow were assessed at days ϩ28, ϩ56, and ϩ84 after transplantation using fluorescence in situ hybridization analyses for recipients of sex-mismatched transplants [23] and polymerase chain reaction-based analyses of variable number tandem repeats for recipients of sex-matched transplants [24] .
Acute and chronic GVHD were graded as described [25] . Prophylactic therapies against Pneumocystis carinii, Candida infections, herpes simplex virus, and cytomegalovirus were administered as described [26] [27] [28] [29] .
Tumor responses were assessed using standard criteria. Patients were eligible for DLI if their immunosuppression was discontinued, they were without evidence of acute or clinical extensive chronic GVHD, and they had persistence or progression of the underlying disease. The first DLI included a dose of 1 ϫ 10 7
CD3
ϩ cells/kg; the second (if indicated) a dose of 3.2 ϫ 10 7 CD3 ϩ cells/kg. Seven patients, all with HLA-identical related donors, received 1 or 2 DLI for relapsed or progressive disease.
Statistical Analysis
Overall survival (OS) and progression-free survival (PFS) were estimated using the Kaplan-Meier method, and TRM and relapse-related mortality were summarized using cumulative incidence estimates [30] . Relapse or disease progression was regarded as a competing risk for TRM, and death without relapse or progression was regarded as a competing risk for relapse-related mortality. Cox regression models were used to examine the association of various clinical risk factors with the hazard of failure from death or progression [31] . Factors examined included the following: type of donor (HLA-matched related versus unrelated), age at nonmyeloablative HCT (analyzed as a continuous variable), time from most recent conventional HCT to allografting after nonmyeloablative conditioning, previous TBI, previous chest irradiation, stages of diseases at the time of nonmyeloablative HCT (untreated, treatment sensitive, or treatment refractory), and diagnoses (HD, NHL-aggressive, MM, and other). Acute and chronic GVHD were considered as time-dependent covariates in regression models for relapse or progression and mortality. The statistical significance of the correlation between risk factors was examined using the chi-square test if each factor was categorical or the Wilcoxon rank-sum test if one of the factors was continuous. Two-sided P values resulting from the regression models were derived from the Wald test, and no adjustments were made for multiple comparisons. Data as of March 1, 2002 , were subsequently analyzed.
RESULTS
Engraftment
Complete chimerism data were available for 46 patients. Median percentages of donor chimerism of the peripheral blood T compartment are shown in 
One patient with refractory secondary AML rejected the unrelated donor marrow graft (2.0 ϫ 10 6 CD34/kg) 33 days after HCT and died of relapse on day ϩ77. The remaining 45 patients for whom chimerism data were available all had sustained engraftment.
The median number of days with absolute neutrophil counts (ANC) Ͻ500/L was 1 (range, 0-41), and 24 patients maintained ANCs Ͼ500/L after HCT. The median ANC nadir was 455 (range, 0-1720)/L. The median platelet nadir was 37,000 (range, 0-177,000)/L, and the median number of days with platelet counts Ͻ20,000/L was 0 (range, 0-41).
Thirty-one patients (58%) required no platelet transfusions. Among the remaining 24 patients, a median of 0 (range, 0-213) platelet units were transfused. Seventeen patients (32%) required no red blood cell transfusions, whereas 38 patients received a median of 2 (range, 0-22) red blood cell units.
Toxicities
Patients at the University of Leipzig (n ϭ 3) had scheduled hospital admissions for HCT. Data regarding hospitalization were available for 51 of the 52 remaining patients who were eligible for outpatient transplantation. Eleven (22%) did not require hospitalization within the first 60 days after HCT. The remainder were hospitalized for a median of 8 days (range, 1-60 days).
The incidence of grades II, III, and IV acute GVHD for the 31 patients with HLA-matched related donors was 29%, 13%, and 6%, respectively. Among 21 patients with related donors and greater than 100 days of follow-up, 14 (67%) required extended immunosuppressive treatment for chronic GVHD. The incidence of grades II, III, and IV acute GVHD for the 24 patients with HLA-matched unrelated donors was 38%, 8%, and 4%, respectively. Among 18 patients with unrelated donors followed up for more than 100 days, 10 (56%) required treatment for chronic GVHD.
TRM rate at day 100 was 11% with an estimated 1-year TRM rate of 20% (95% confidence interval [CI], 9%-31%). Causes of death included GVHD (n ϭ 5), infection (n ϭ 7), and multiorgan failure (n ϭ 9), with 7 of 11 patients having more than 1 cause of death. A death due to suicide occurred but was not considered transplantation related.
Results of univariate Cox regression models for TRM are described in Table 2 . Previous TBI (hazard ratio [HR] 3.3; P ϭ .08) and untreated disease (HR 2.4; P ϭ .18) were associated with increased hazards of TRM, whereas having an unrelated donor (HR 0.3; P ϭ .08) conferred a decreased hazard of TRM, although none of these associations reached statistical significance.
Donor Lymphocyte Infusions
Seven patients received 1 to 2 DLIs for relapsed or progressive disease. All 7 had received HLA-matched related donor grafts. The diagnoses of the patients receiving DLI were HD (n ϭ 3), MM (n ϭ 3), and NHL, aggressive subtype (n ϭ 1). One patient remained alive with disease progression with follow-up of 735 days. Five relapse-related deaths and 1 transplantation-related death have occurred after DLI.
Relapse and Survival
Overall, the relapse mortality rate at day 100 was 13% with an estimated 1-year relapse-related mortality rate of 31% (95% CI, 17%-44%). With a median follow-up of 368 days (range, 173-796 days) among all survivors, the estimated OS and PFS rates at 1 year were 49% (95% CI, 35%-62%) and 28% (95% CI, 16%-41%), respectively ( Figure 2) .
Results of univariate Cox regression models for overall mortality and PFS are described in Table 3 and  Table 4 . Untreated disease at the time of allografting after nonmyeloablative conditioning (HR 2.4; P ϭ .04) and previous TBI (HR 2.2; P ϭ .11) were associated with suggestively increased hazards of overall mortality, whereas untreated disease suggested an increased hazard of disease progression (HR 2.1; P ϭ .06). MRD indicates matched related donor; NHL-A, nonHodgkin's lymphoma, aggressive subtype; NMT, nonmyeloablative transplantation; URD, unrelated donor; XRT, radiation therapy.
*Modeled as a continuous variable, HR presented in terms of an increase in age of 10 y.
†Modeled as a continuous variable, HR presented in terms of an increase in time of 10 months.
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The Impact of GVHD on Relapse or Progression and Mortality
The hazard of disease relapse or progression was lower among patients with grades II to IV acute GVHD compared with that among patients with grades 0 to I GVHD; however, the difference was not statistically significant (HR ϭ 0.7; 95% CI, 0.3-1.6; P ϭ .36). Conversely, the hazard of mortality was increased among patients with grades II to IV acute GVHD (HR ϭ 1.5; 95% CI, 0.7-3.1; P ϭ .27), although this difference also was not statistically significant. Similarly, the hazard of relapse or progression decreased among patients with chronic GVHD (HR ϭ 0.8; 95% CI, 0.2-2.7; P ϭ .70) compared with those without chronic GVHD with an increased hazard of mortality (HR ϭ 1.3; 95% CI, 0.5-3.8; P ϭ .61). Excluding patients with grade IV GVHD (whose transplantation-related death would preclude relapse or progression) yielded similar results with a decreased hazard of relapse (HR ϭ 0.8; 95% CI, 0.3-1.8; P ϭ .52) being offset by an increased hazard of mortality (HR ϭ 1.3; 95% CI, 0.6-2.8; P ϭ .52).
DISCUSSION
We retrospectively evaluated the results of 55 patients who received allografts after nonmyeloablative conditioning from either related or unrelated HLAmatched donors after failing conventional HCT. The estimated probabilities of OS, PFS, and TRM 1 year after nonmyeloablative conditioning and HCT were 49%, 28%, and 20%, respectively. Having untreated disease at the time of HCT appeared to increase the hazard of failure due to death or progression. Previous TBI increased the hazard of TRM; however, the power to detect a statistically significant difference was limited by the number of transplantation-related deaths.
The low rejection rate observed among current patients likely reflected effective immunosuppression from both the transplantation regimen as well as the previous treatment. The 1 patient who rejected his graft had refractory secondary AML and received an Figure 2 . OS, PFS, and TRM for 54 patients who had failed conventional HCT and were given HLA-matched related or unrelated donor allografts after nonmyeloablative conditioning. unrelated donor marrow infusion with a low CD34 ϩ cell dose. In a recent analysis of other patients with unrelated donor allografts who received the current nonmyeloablative regimen, the diagnosis of MDS and receipt of marrow compared with G-PBMC as the stem cell source conferred increased risks of rejection [21] .
Among the 6 patients (all with unrelated donors) who received marrow infusions, all experienced relapse or progressive disease, and 5 have died of their disease. The limited number of patients receiving marrow precluded a more rigorous comparison of marrow and G-PBMC as stem cell sources among current patients who failed conventional HCT. However, a recent analysis of all patients, including those with other malignancies and without previous autografts, receiving unrelated donor allografts with this regimen, showed that G-PBMC as the stem cell source conferred not only superior engraftment, but also better OS and PFS compared with marrow [21] . This is the largest reported series of allografting after nonmyeloablative conditioning as salvage therapy after failed high-dose conventional HCT. Nagler et al. [32] evaluated 12 patients (median age, 33 years; range, 8-63 years) who received allografts from HLAidentical siblings for relapsed disease or secondary malignancies after failed autologous HCT. Conditioning consisted of fludarabine, busulfan, and antithymocyte globulin. One nonrelapse death occurred, and 6 patients were free of disease with a median follow-up of 23 months. Actuarial and disease-free survival rates at 34 months were 56% and 50%, respectively.
Dey et al. [33] described 13 patients (median age, 43 years; range, 24-62 years) who failed autologous HCT and received HLA-matched related donor allografts after conditioning with cyclophosphamide and antithymocyte globulin with or without thymic irradiation. Only 1 nonrelapse death occurred. Median survival was 10 months (range, 3-39 months) with 2-year estimates of overall and disease-free survival rates of 45% and 38%, respectively.
Devine et al. [34] studied 11 patients (median age, 41 years; range, 22-58 years) who relapsed after autologous or allogeneic HCT and received second transplants from HLA-identical or mismatched related donors after a fludarabine-based regimen. Whereas full donor engraftment was achieved in all but 1 patient, 10 of 11 died a median of 140 days (range, 9-996 days) after transplantation; 5 of relapse and 5 of nonrelapse causes. Because only one of the patients was in CR at the time of HCT, the authors suggested that advanced disease at the time of allografting after nonmyeloablative conditioning had a negative impact on outcome.
Although length of follow-up is short, allografting after nonmyeloablative conditioning appears to be a feasible treatment option for patients who have failed mostly autologous, conventional HCT. TRM with this approach is low. Having untreated disease at the time of allografting after nonmyeloablative conditioning or previous TBI may confer a worse outcome. However, age, duration from conventional HCT, diagnoses, and type of donor did not appear to significantly influence overall mortality.
